Oxis Turbohaler 4.5 µg/dosis inhalatiepdr. multidos. cont. Belgia - hollandi - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

oxis turbohaler 4.5 µg/dosis inhalatiepdr. multidos. cont.

astrazeneca sa-nv - formoterolfumaraatdihydraat 10 mg/g - inhalatiepoeder - 4,5 µg/dose - formoterolfumaraatdihydraat 4.5 µg/dosis - formoterol

Plendil 10 mg Retard tabl. verl. afgifte Belgia - hollandi - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

plendil 10 mg retard tabl. verl. afgifte

astrazeneca sa-nv - felodipine 10 mg - tablet met verlengde afgifte - felodipine 10 mg - felodipine

Plendil 5 mg Retard tabl. verl. afgifte Belgia - hollandi - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

plendil 5 mg retard tabl. verl. afgifte

astrazeneca sa-nv - felodipine 5 mg - tablet met verlengde afgifte - felodipine 5 mg - felodipine

Rhinocort Turbohaler 100 100 µg/dose snuifpoeder inhalator Belgia - hollandi - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

rhinocort turbohaler 100 100 µg/dose snuifpoeder inhalator

astrazeneca sa-nv - budesonide 100 µg/dosis - snuifpoeder - 100 µg - budesonide 100 µg/dosis - budesonide

Tenif 50 mg - 20 mg harde caps. Belgia - hollandi - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

tenif 50 mg - 20 mg harde caps.

astrazeneca sa-nv - nifedipine 20 mg; atenolol 50 mg - capsule, hard - 50 mg - 20 mg - nifedipine 20 mg; atenolol 50 mg - atenolol and other antihypertensives

Trixeo Aerosphere Euroopa Liit - hollandi - EMA (European Medicines Agency)

trixeo aerosphere

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - longaandoening, chronisch obstructief - geneesmiddelen voor obstructieve aandoeningen van de luchtwegen, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Calquence Euroopa Liit - hollandi - EMA (European Medicines Agency)

calquence

astrazeneca ab - acalabrutinib - leukemie, lymfocytisch, chronisch, b-cel - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Lumoxiti Euroopa Liit - hollandi - EMA (European Medicines Agency)

lumoxiti

astrazeneca ab - moxetumomab pasudotox - leukemie, harige cel - antineoplastische middelen - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Evusheld Euroopa Liit - hollandi - EMA (European Medicines Agency)

evusheld

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Saphnelo Euroopa Liit - hollandi - EMA (European Medicines Agency)

saphnelo

astrazeneca ab - anifrolumab - lupus erythematosus, systemisch - immunosuppressiva - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.